Cargando…
Short-form Ron is a novel determinant of ovarian cancer initiation and progression
Short-form Ron (sfRon) is an understudied, alternative isoform of the full-length Ron receptor tyrosine kinase. In contrast to Ron, which has been shown to be an important player in many cancers, little is known about the role of sfRon in cancer pathogenesis. Here we report the striking discovery th...
Autores principales: | Moxley, Katherine M., Wang, Luyao, Welm, Alana L., Bieniasz, Magdalena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979590/ https://www.ncbi.nlm.nih.gov/pubmed/27551332 http://dx.doi.org/10.18632/genesandcancer.109 |
Ejemplares similares
-
Multi-kinase targeted therapy as a promising treatment strategy for ovarian tumors expressing sfRon receptor
por: Wang, Luyao, et al.
Publicado: (2020) -
Blocking Short-Form Ron Eliminates Breast Cancer Metastases through Accumulation of Stem-Like CD4(+) T Cells That Subvert Immunosuppression
por: Lai, Shu-Chin Alicia, et al.
Publicado: (2021) -
RON promotes the metastatic spread of breast carcinomas by subverting antitumor immune responses
por: Eyob, Henok, et al.
Publicado: (2013) -
mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential
por: Faham, Najme, et al.
Publicado: (2018) -
Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer
por: Wu, Zheng, et al.
Publicado: (2015)